SIRT3 and neoplasm: Respiratory tumor cells carry unique vulnerabilities that can distinguish them from normal respiratory cells, such as defective mitochondria and decreased NFκB that could be targeted by therapies that include Sirt3 activation, which kills tumor cells with defective mitochondria by promotion of mitochondrial fusion and increased reactive oxygen generation, while, at the same time, decreasing NFκB activation.